EFMC-ISMC 2018

The Final Programme is available here!

Late abstract submission is open until August 31!


Follow us!

EFMC-ISMC EFMC-ISMC EFMC-ISMC

Spread the word with #EFMC_ISMC

Programme Schedule

Sunday September 2, 2018
13:30Registration
16:00Opening Ceremony
Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
16:20Chair
Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
Zika Virus: An Old Virus with a New Face
Prof. Tatjana AVSIC-ZUPANC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
16:50Chair
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
It’s a Small-Molecule World: Medicinal Chemistry Challenges and Opportunities for the Next Decade
Dr Bayard HUCK
(MERCK BIOPHARMA, Darmstadt, Germany)
17:20Award Ceremony
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
17:40Chair
Prof. Henk TIMMERMAN
(VU UNIVERSITY AMSTERDAM, Oegstgeest, The Netherlands)
NAUTA AWARD FOR PHARMACOCHEMISTRY
Tools and Drugs for Purine Targets - Important Players in Inflammation and Cancer
Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)
18:25Chair
Prof. Hans Ulrich STILZ
(NOVO NORDISK, Malov, Denmark)
Synthetic Glycoconjugate Vaccines against Bacterial Infections
Prof. Peter H. SEEBERGER
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany)
19:10Welcome Reception
20:30End of the Day
Monday September 3, 2018
08:30Chair
Dr Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)
UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
How Best to Discover Bioactive Small Molecules?
Prof. Adam NELSON
(UNIVERSITY OF LEEDS, Leeds, United Kingdom)
09:15Chair
Prof. Roberto DI SANTO
(SAPIENZA UNIVERSITY OF ROME, Rome, Italy)
The Therapeutic Challenge of the New Era: Developing and Making Available Life Changing Treatment to Patients with Rare Diseases
Dr Diego ARDIGO
(CHIESI GROUP, PARMA, Italy)
10:00Exhibition & Coffee
Session 1 'Technologies'

Artificial Intelligence Applications in Medicinal Chemistry
Session 2 'Therapeutic Areas'

Immuno-Oncology: Novel Therapeutic Opportunities
Session 3 'Chemical Biology'

Glycans in Medicinal Chemistry: Carbohydrate-Based Vaccines
(EuCheMS Session)
10:30Session Chair
Dr Jonas BOSTRÖM
(ASTRAZENECA, Mölndal, Sweden)
10:30Session Chair
Dr Luc VAN HIJFTE
(SCT & MERCACHEM-SYNCOM, Nijmegen, The Netherlands)
10:30Session Chair
Dr Sonsoles MARTIN-SANTAMARIA
(BIOLOGICAL RESEARCH CENTER, Madrid, Spain)
10:35Artificial Intelligence. Not Just Another Name for in Silico Design
Dr David E. LEAHY
(THE DISCOVERY BUS LTD, Macclesfield, United Kingdom)
10:35Small Molecule Immune Checkpoint Antagonists for Cancer Therapy
Dr Murali RAMACHANDRA
(AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India)
10:35Breaking the Limits in Analyzing Carbohydrate Recognition by NMR
Dr Jesus JIMENEZ-BARBERO
(CIC BIOGUNE, Derio, Spain)
11:15Re-Energising Small Molecule Drug Discovery
Dr Willem VAN HOORN
(EXSCIENTIA, Dundee, United Kingdom)
11:15Title to be announced
Prof. Stefan KRAUSS
(UNIVERSITY OF OSLO, Oslo, Norway)
11:15Targeting of Cancer Specific Glycopeptide Epitopes
Prof. Hans WANDALL
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)
11:35Invited speaker to be confirmed
11:35Small Molecules Inhibiting PD1-PDL1 Immune Checkpoint
Dr Shabnam SHAABANI
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)
11:35A Multidisciplinary Strategy to Synthetic Carbohydrate-Based Conjugates for Vaccination Against Shigella: from Concept to First-in-Human Study
Dr Laurence MULARD
(INSTITUT PASTEUR, Paris, France)
11:55Potency and Patents, New Arenas for Matched Molecular Pair Analysis in the AI World
Dr Al DOSSETTER
(MEDCHEMICA LIMITED, Macclesfield, United Kingdom)
11:55New Small-Molecule Immune Checkpoint Inhibitors: A Step Forward in Cancer Immunotherapy
Ms Ana Rita DE CARVALHO ACURCIO
(UNIVERSITY OF LISBON, Lisbon, Portugal)
11:55Glycoside Antagonists of Bacterial Lectins: New Treatment Options for Recurrent and Antibiotic Resistant UTI
Prof. James JANETKA
(WASHINGTON UNIVERSITY IN SAINT LOUIS, Saint Louis, United States)
12:15Exhibition & Lunch
Session 4 'Technologies'

Timing is Everything: Target Binding Kinetics and Pharmacokinetics
Session 5 'Therapeutic Areas'

Life Science at the Interface of Agro and Pharma
Session 6 'Chemical Biology'

Recent Advances in Targeted Protein Degradation
13:15Session Chair
Prof. Ad P. IJZERMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
13:15Session Chair
Dr Franz VON NUSSBAUM
(BAYER, Monheim, Germany)
13:15Session Chair
Dr Gregory HOLLINGWORTH
(NOVARTIS PHARMA AG, Basel, Switzerland)
13:20"Micro-Pharmacokinetics”: How Local Drug Concentration Influences Observed Binding Kinetics
Prof. Steven CHARLTON
(UNIVERSITY OF NOTTINGHAM, Nottingham, United Kingdom)
13:20A New Target in Fungal Protein Biosynthesis: Shared Learnings for AgChem and MedChem
Dr David BERNIER
(BAYER S.A.S. - CROPSCIENCE DIVISION, Lyon, France)
13:20Recent Advances in Bifunctional Degrader Molecules (e.g. SNIPER) for Targeted Protein Degradation via the Ubiquitin Proteasome System; Status and Outlook
Dr Mikihiko NAITO
(NATIONAL INSTITUTE OF HEALTH SCIENCES, Tokyo, Japan)
14:00Allosteric Modulation of the mGlu2 Receptor: from Structure-Kinetic Relationships to in vivo Efficacy
(2017 MedChemComm Emerging Investigator Lectureship)
Dr Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
14:00Natural Products as Leads in Agrochemistry
Dr Joachim RHEINHEIMER
(BASF, Ludwigshafen am Rhein, Germany)
14:00Targeting Transcription and Translation Factors for Degradation with Low Molecular Weight Cereblon Modulators
Dr Philip CHAMBERLAIN
(CELGENE, Alameda, United States)
14:20Target Binding Kinetics and its Relevance in the in vivo Context
Dr Liesbeth DE LANGE
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
14:20Synthesis and Fungicidal Activity of Novel Inhibitors of Oxysterol Binding Protein
Dr Laura QUARANTA
(SYNGENTA AG, Basel, Switzerland)
14:20The Zinc-Degrome
Dr Nicolas THOMÄ
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
14:40Large-Scale Analysis of Kinase Inhibitors Target Binding Kinetics and its Implications for Drug Discovery
Dr Victoria GEORGI
(BAYER AG, Berlin, Germany)
14:40Targeting Non Essential Bacterial Targets as a Novel Route to Counteract Bacterial Resistance
Prof. Gabriele COSTANTINO
(UNIVERSITY OF PARMA, Parma, Italy)
14:40Drugging the Fbw7 E3 Ligase with a Combined Computational and Biophysical Approach
Dr Carles GALDEANO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)
15:00Exhibition & Coffee
Session 7

First Time Disclosures
15:30Session Chair
Dr Emmanuel PINARD
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
15:35Discovery of RG7916, a Selective SMN2 Splicing Modifier for the Treatment of Spinal Muscular Atrophy
Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
16:05Discovery of LOU064, a Covalent BTK Inhibitor with Best in Class Selectivity
Dr Robert PULZ
(NOVARTIS PHARMA, Basel, Switzerland)
16:35Discovery of a Novel Oral NO- and Haem-Independent sGC Activator BAY 1101042
Dr Michael G. HAHN
(BAYER HEALTHCARE, Wuppertal, Germany)
17:05First Time Disclosure of BI 409306, a First in Class PDE9 Inhibitor for the Treatment of CNS Diseases
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany)
17:35Poster Session 1 & Networking
19:30End of the Day
Tuesday September 4, 2018
08:30Chair
Dr Josep Jr. PROUS
(PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, Barcelona, Spain)
PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Activity-Based Proteomics - Protein and Ligand Discovery on a Global Scale
Prof. Benjamin CRAVATT
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)
09:15Chair
Dr Phil JONES
(BIOASCENT, Glasgow, United Kingdom)
Sugars and Proteins
Prof. Benjamin DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom)
10:00Exhibition & Coffee
Session 8 'Technologies'

New Chemical Modalities in Medicinal Chemistry
Session 9 'Therapeutic Areas'

Targeting Aggregated Proteins in Neurodegenerative Diseases with Small Molecules
Sessions 10 'Chemical Biology'

Targeting the STING Pathway (Stimulator of Interferon Genes)
10:30Session Chair
Dr Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Gothenburg, Sweden)
10:30Session Chair
Dr Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)
10:30Session Chair
Dr Thorsten OOST
(BOEHRINGER INGELHEIM, Biberach, Germany)
10:35New Modalities for Complex and Unprecedented Biological Targets
Dr Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Gothenburg, Sweden)
10:35Understanding Aggregation Inhibition of Alpha-Synuclein and Tau by Small Molecules
Prof. Markus ZWECKSTETTER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)
10:35Title to be announced
Prof. Andrea ABLASSER
(EPFL, Lausanne, Switzerland)
11:15Cell Permeability with Beyond ‘Rule of 5’ Modalities – Do We Understand How This Works?
Dr Nick TERRETT
(MERCK SHARP & DOHME RESEARCH GMBH (MSD), Kriens, Switzerland)
11:15Discovery of Peptidomimetics Targeting Protein-Protein Interactions of Alpha-Synuclein
Dr Wolfgang WRASIDLO
(UNIVERSITY OF CALIFORNIA SAN DIEGO, La Jolla, United States)
11:15Modification of Cyclic Dinucleotides to Enhance Modulation of the Innate Immune Response
Dr Diane COE
(GLAXOSMITHKLINE, Stevenage, United Kingdom)
11:35Novel Hybrid Macrocyclic Modalities for Structure-Based Protein Mimetics
Dr Stephanie GUERET
(ASTRAZENECA-MAX PLANCK INSTITUTE SATELLITE UNIT, Dortmund, Germany)
11:35Targeting the Monomeric Intrinsically Disordered Structural State of Tau and Alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Alzheimer's and Parkinson’s Disease.
Dr Gergely TOTH
(CANTABIO PHARMACEUTICALS INC., Sunnyvale, United States)
11:35Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity
Dr Cedric BOULARAN
(INVIVOGEN, Toulouse, France)
11:55Small-Molecule Stabilization of Protein-Protein Interactions by Natural Products, Supramolecular Ligands, Fragments and Macrocycles
Dr Christian OTTMANN
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands)
11:55Brain-Penetrant Autophagy Modulators for Treating Neurodegenerative Diseases
Dr Steve ANDREWS
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
11:55In Vivo Anti-Viral and -Tumor Effect Of 3’3’-cAIMP STING Activation
Dr Martin K. THOMSEN
(AARHUS UNIVERSITY, Aarhus C, Denmark)
12:15Exhibition & Lunch
12:15Chemical Computing Group Workshop
MOEsaic: The application of Matched Molecular Pair Analysis to SAR Exploration
Flash Posters 1Flash Posters 2 Flash Posters 3
13:15Opportunity for 10 young scientists to present a summary of their poster
13:15Opportunity for 10 young scientists to present a summary of their poster
13:15Opportunity for 10 young scientists to present a summary of their poster
Session 11 'Technologies'

Expanding Medicinal Chemists’ Synthetic Toolbox
Session 12 'Therapeutic Areas'

Breakthroughs in Polypharmacology Towards Neurological Disorders
(ACS Session)
Session 13 'Chemical Biology'

Chemical Biology Approaches to Target Identification
13:45Session Chair
Prof. Gyorgy KESERU
(RESEARCH CENTRE FOR NATURAL SCIENCES, HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
13:45Session Chair
Prof. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)
13:45Session Chair
Prof. Herbert WALDMANN
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
13:50Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis
Prof. Karl GADEMANN
(UNIVERSITY OF ZURICH, Zurich, Switzerland)
13:50Multi-Functional Treatments for Multi-Factorial Neurodegenerative Disorders: the Challenge of Alzheimer's Disease
Dr Mark J. MILLAN
(INSTITUT DE RECHERCHES SERVIER, Croissy-sur-Seine, France)
13:50Activity-Based Glycosidase Profiling in Biomedicine and Biotechnology
Prof. Hermen OVERKLEEFT
(LEIDEN UNIVERSITY, Leiden, The Netherlands)
14:30Stuck in a Rut with Old Chemistry
Dr Jonas BOSTRÖM
(ASTRAZENECA, Mölndal, Sweden)
14:30Exploiting Kinase Polypharmacology to Promote Nerve Regeneration
Dr Hassan AL-ALI
(THE MIAMI PROJECT TO CURE PARALYSIS, Miami, United States)
14:30An Iron Hand over Cancer Stem Cells
Dr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France)
14:50New Chemical Libraries in Exploration of Chemical Space
Prof. Jurij SVETE
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
14:50In silico Polypolpharmacology
Dr Giovanni BOTTEGONI
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)
14:50Charting the Structure-Resistance Landscape of Novel Antibiotics
Mr Tamas REVESZ
(BIOLOGICAL RESEARCH CENTRE, HUNGARIAN ACADEMY OF SCIENCES, Szeged, Hungary)
15:10Integrated System for the Expedited Generation and Characterization of Drug-Like Libraries for Hit-To-Lead Explorations
Prof. Antimo GIOIELLO
(UNIVERSITY OF PERUGIA, Perugia, Italy)
15:10Metabotropic Glutamate Receptor Type 2 Positive Allosteric Modulators (mGlu2 Receptor PAMS) as a Transformational Epilepsy Treatment
Dr Jose CID
(JANSSEN R&D, Toledo, Spain)
15:10Buruli Ulcer and the mTOR Pathway: Total Synthesis, Structure-Activity and Target Elucidation Studies of Mycolactones
Dr Matthias GEHRINGER
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany)
15:30Exhibition & Coffee
Flash Posters 4Flash Posters 5Flash Posters 6
16:00Opportunity for 15 young scientists to present a summary of their poster
16:16Opportunity for 15 young scientists to present a summary of their poster
16:00Opportunity for 15 young scientists to present a summary of their poster
16:45Poster Session 2 & Networking
18:45End of Poster Session
20:00Concert
Wednesday September 5, 2018
08:30Chair
Dr Jürgen MACK
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)
Development of Non-Nucleosidic Compounds against DNA Viruses of the Herpes Group. The Era After Nucleosides: Letermovir and Pritelivir
Dr Helga RÜBSAMEN-SCHAEFF
(AICURIS GMBH & CO. KG, Wuppertal, Germany)
09:15EFMC Prize Ceremony
Dr Matthew TOZER (CONSULTANT, Cambridge, United Kingdom)
Prof. Rui MOREIRA (UNIVERSITY OF LISBON, Lisbon, Portugal)
09:20EFMC Prize for a Young Medicinal Chemist in Industry
The Challenges of Restoring Programmed Cell Death Through MCL1 Inhibition
Dr Marton CSEKEI
(SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary)
09:40EFMC Prize for a Young Medicinal Chemist in Academia
Dr Alexander TITZ
(HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL SCIENCES, Saarbrücken, Germany)
10:00Exhibition & Coffee
Session 14 'Technologies'

Development of New Synthetic Methodologies for Drug Discovery
(CPA Session)
Session 15 'Therapeutic Areas'

Upcoming Treatments for NASH and Other Fibrotic Diseases
Session 16 'Chemical Biology'

Recent Developments in Kinase Inhibitors
10:30Session Chair
Dr Ming-Qiang ZHANG
(AMGEN, Shanghai City, China)
10:30Session Chair
Prof. Roberto PELLICCIARI
(TES PHARMA SRL, Corciano, Italy)
10:30Session chair
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)
10:35Sulfur- and Silicon-Based Fluorination Reagents for Medicinal Chemistry
Dr Jinbo HU
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China)
10:35Obeticholic Acid, Leading in the NASH Race. History and Perspectives
Prof. Roberto PELLICCIARI
(TES PHARMA SRL, Corciano, Italy)
10:35EGFR Triple Mutant - Recent Set-Backs and New Hopes in Fighting Mutant Non-Small Cell Lung Cancer
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)
11:15Upgrading Cross Coupling toward Biaryl Scaffolds
Dr Zhang-Jie SHI
(FUDAN UNIVERSITY, Shanghai, China)
11:15Discovery of LJN452 (Tropifexor), a Highly Potent, Non-Bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and NASH
Dr David TULLY
(NOVARTIS, Emeryville, United States)
11:15Design and Rationale for Exquisite Selectivity of Preclinical and Clinical Kinase Inhibitors
Dr Laurent SCHIO
(SANOFI, Vitry sur Seine, France)
11:35Practical Asymmetric Hydrogenation
Prof. Xumu ZHANG
(SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY, Guangdong, China)
11:35The First Class of Orally Available Mono-Saccharide Galectin-3 Inhibitors for Treatment of Fibrosis (NASH) and Cancer
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden)
11:35Chemical Probes for New Therapeutic Concept Discovery
Dr Peter ETTMAYER
(BOEHRINGER-INGELHEIM, Vienna, Austria)
11:55Asymmetric Aldol Reactions of Heterocyclic Dienolsilanes and α,β-Unsaturated Carbonyl Derived Dienolsilanes
Prof. Fener CHEN
(FUDAN UNIVERSITY, China)
11:55Development of Small-Molecule Inhibitors of Adipose Triglyceride Lipase (ATGL)
Ms Anna MIGGLAUTSCH
(TU GRAZ, Graz, Austria)
11:55Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn’s Disease, and Other Autoimmune Conditions
Dr Brian GERSTENBERGER
(PFIZER, Cambridge, United States)
12:15Exhibition & Lunch
12:15Schrödinger Workshop
Data Driven Drug Design – Using LiveDesign
Session 17

Emerging Topics
Session 18 'Therapeutic Areas'

Addressing Infectious Diseases in the Developing Countries
(AFMC Session)
Session 19 'Chemical Biology'

The Sphingosine-1-Phosphate Axis: Therapeutic Potential in Inflammation, Cancer, and More
(ACS Session)
13:15Session Chair
Prof. Gabriele COSTANTINO
(UNIVERSITY OF PARMA, Parma, Italy)
13:15Session Chair
Dr Renate GRIFFITH
(UNIVERSITY OF NEW SOUTH WALES, UNSW Sydney, Australia)
13:15Session Chair
Dr Tony LEE
(GILEAD SCIENCES, Seattle, United States)
13:20Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signaling for the Maintainance of Synaptic Function in Alzheimer’s Disease
Prof. Paul FISH
(ARUK UCL DRUG DISCOVERY INSTITUTE, London, United Kingdom)
13:20All Bugs are Shallow: Open Source Drug Discovery
Prof. Matthew TODD
(UNIVERSITY OF SYDNEY, Sydney, Australia)
13:20Unravelling the Mysteries of the Sphinx: New Therapeutic Targets and Drug Leads from the Phenotypic Screening of Non-Lipid Sphingolipid Mimetics
Prof. Bernard FLYNN
(MONASH UNIVERSITY, Parkville, Australia)
13:40Synthetic Small-Molecule RNA Ligands: Scope and Therapeutic Applications
Prof. Maria DUCA
(UNIVERSITÉ CÔTE D'AZUR, Nice, France)
14:00Towards the Development of Small Molecule Therapy for Chikungunya
Prof. Christina CHAI
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)
14:00Invited speaker to be confirmed
14:00Discovery of First-In-Class, Selective and Noncovalent Small Molecule Inhibitors of DNMT1
Dr Allan JORDAN
(CANCER RESEARCH UK MANCHESTER INSTITUTE, Manchester, United Kingdom)
14:20Identification of New Antimalarial GSK607: An Example of Adaptive and Differentiated Early Drug Development
Dr Esther FERNANDEZ
(GLAXOSMITHKLINE, Tres Cantos, Spain)
14:20Active Site Inhibitors of Sphingosine 1-Phosphate Lyase? Exploring Novel Biology with Tool Compounds
Dr Sven WEILER
(BASILEA PHARMACEUTICA INTERNATIONAL LTD., Basel, Switzerland)
14:20ASTX660, the First Fragment-Derived IAP Antagonist in the Clinic
Dr Steven HOWARD
(ASTEX THERAPEUTICS , Cambridge , United Kingdom)
14:40IUPAC-Richter Prize Lecture
Dr Peter GROOTENHUIS
(VERTEX PHARMACEUTICALS, San Diego, United States)
14:40Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Small Molecules Targeting RNA
Dr Alice SOSIC
(UNIVERSITY OF PADOVA, Padova, Italy)
14:40Controlling Sphingosine-1-Phosphate Levels as a Therapeutic Strategy
Dr Webster L. SANTOS
(VIRGINIA TECH, Blacksburg, United States)
15:00End of the Day
15:30Excursions
20:00Banquet
Thursday September 6, 2018
Session 20 'Technologies'

Recent Developments in Nucleoside Medicinal Chemistry
Session 21 'Therapeutic Areas'

Inflammatory and Autoimmune Diseases
Session 22 'Chemical Biology'

Enzyme Activators and Positive Allosteric Modulators
08:30Session Chair
Dr Jared CUMMING
(MSD, Boston, United States)
08:30Session Chair
Prof. Stanislav GOBEC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
08:30Session Chair
Prof. Joachim MITTENDORF
(BAYER AG, Wuppertal, Germany)
08:35Cyclic Dinucleotide STING Agonists as Anti-Tumor Agents
Dr Wes TROTTER
(MSD, Boston, United States)
08:35Nonpeptidic Selective Inhibitors of Immunoproteasome
Prof. Stanislav GOBEC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
08:35Design, Synthesis, and Mechanism of β-Glucocerebrosidase Activators for Gaucher’s and Parkinson’s Diseases
Prof. Richard B. SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)
09:15Discovery of JNJ-64619178 as a Potent and Selective PRMT5 Inhibitor for the Treatment of Lung and Hematologic Cancers
Dr Jan Willem THURING
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)
09:15Small-Molecule Immunomodulators that Target Toll-Like Receptors
Prof. Hang YIN
(TSINGHUA UNIVERSITY, Beijing, China)
09:15Positive Allosteric Modulators of the GABA-B Receptor
Dr Sean C. TURNER
(ABBVIE, Ludwigshafen am Rhein, Germany)
09:35Design and Synthesis of Congerners of Cyclic ADP-Ribose, a Ca2+-Mobilizing Second Messenger, Toward Identification of the Target Protein
Prof. Satoshi SHUTO
(HOKKAIDO UNIVERSITY, Sapporo, Japan)
09:35A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Treat Non-Alcoholic Steatohepatitis
(EFMC-YMCS Presentation Prize)
Dr Daniel MERK
(ETH ZÜRICH, Zürich, Switzerland)
09:35The Value of Orthogonal Techniques for Elucidating Binding Site(s) of GPCR Allosteric Modulators: a Case Study With Positive Allosteric Modulators of Dopamine Receptors
Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium)
09:55Development of Novel Sialyltransferase Inhibitors via Computer Aided Drug Design
Mr Andrew MONTGOMERY
(UNIVERSITY OF WOLLONGONG, Wollongong, Australia)
09:55Discovery of SPL-707: a Potent, Selective, and Orally Bioavailable SPPL2a Inhibitor
Dr Juraj VELCICKY
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
09:55AMPA Receptor Positive Allosteric Modulators Based on New Scaffolds: Design, Synthesis, and Studies
Dr Vladimir A. PALYULIN
(LOMONOSOV MOSCOW STATE UNIVERSITY, Moscow, Russia)
10:15Exhibition & Coffee (brunch)
Session 23 'Technologies'

PET Imaging as a Tool for in Vivo Drug Evaluation and Development
(EANM Session)
Session 24

Late Breaking News
Session 25 'Therapeutic Areas'

Cardiometabolic Diseases
10:45Session Chair
Prof. Antony GEE
(KING'S COLLEGE LONDON, London, United Kingdom)
10:45Session Chair
Dr Anna KARAWAJCZYK
(SELVITA, Krakow, Poland)
10:45Session Chair
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
10:50PET Molecular Imaging – an Overview
Prof. Antony GEE
(KING'S COLLEGE LONDON, London, United Kingdom)
10:50First Disclosure of the Clinical Candidate BAY-840, a Potent And Selective hBradykinin B1 Antagonist for the Treatment of Chronic Inflammatory Diseases, Generated within the Bayer-Evotec Strategic Alliance
Dr Stefan BÄURLE
(BAYER AG, Berlin, Germany)
10:50C-Natruiretic Peptide Agonists for Cardiovascular Disease
Prof. David SELWOOD
(UNIVERSITY COLLEGE LONDON, London, United Kingdom)
11:30PET in Neuroscience Drug Discovery and Development
Dr Magnus SCHOU
(KAROLINSKA INSTITUTE, Stockholm, Sweden)
11:10Discovery of GDC-0077: A Highly Selective Inhibitor and Degrader of Mutant PI3K-Alpha
Dr Jamie KNIGHT
(CHARLES RIVER, Harlow, United Kingdom)
11:30The Discovery of Semaglutide? A Journey from Ala Scan to Structural Design of GLP-1 Analogues
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
11:50PET for Oncology Drug Discovery and Development
Prof. Bert WINDHORST
(VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands)
11:30Anti-HBV Drug Discovery Enabled by Structure-Based Drug Design and Phenotypic Screening
Dr Hong SHEN
(ROCHE INNOVATION CENTER, Shanghai, China)
11:50Discovery and Optimization of Non-Covalent, Selective, and Bioavailable Small Molecule Inhibitors of the KEAP1-Nrf2 Pathway
Dr Hauke SZILLAT
(SANOFI, Frankfurt, Germany)
12:10Discovery of Candidates for PET Molecular Imaging of Pathological TDP-43 Aggregates in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Patients
Dr Vincent DARMENCY
(AC IMMUNE SA, Lausanne, Switzerland)
11:50Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 that Enables Transient Target Engagement for the Treatment of Haematological Malignancies
Dr Bernard BARLAAM
(ASTRAZENECA, Cambridge, United Kingdom)
12:10Discovery and Clinical Evaluation of MK-8150, a Novel Nitric Oxide Donor with a Unique Mechanism of Nitric Oxide Release
Dr Amjad ALI
(MERCK, SHARP & DOHME, Kenilworth, United States)
12:10The Discovery of CNP520, an Amino-1,4-Oxazine BACE Inhibitor in Prevention Studies
Dr Rainer MACHAUER
(NOVARTIS PHARMA AG, Basel, Switzerland)
12:30Chair
Dr Cornelia ZUMBRUNN
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland)
Smart Chemical Probes: from Bromodomain Ligands to Natural Products
Prof. Cristina NEVADO
(UNIVERSITY OF ZURICH, Zurich, Switzerland)
13:15Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2020
Prof. Marko ANDERLUH (UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys